NEW YORK – Cancer Genetics reported after the close of the market on Wednesday that its first quarter revenues fell 22 percent year over year, mainly due to a non-recurring IP licensing agreement a year ago.
For the three months ended March 31, Rutherford, New Jersey-based Cancer Genetics posted total revenues of $1.4 million versus $1.8 million in the same quarter the year before. In Q1 2019, the firm had $300,000 in revenue from an IP license agreement that was unrelated to its ongoing discovery services business.